1. Introduction {#sec1}
===============

Vaccine-associated paralytic poliomyelitis (VAPP) \[[@B1]\] is the consequence of the replication of vaccine-derived polioviruses (VDPVs) that originate by genetic mutations from the strain contained in the oral polio vaccine (OPV). In fact, the poliovirus (PV) genetic mutability \[[@B2]\] appears to be the molecular basis of VAPP, which throws a shadow over the great success represented by vaccination in fighting PV infection \[[@B3], [@B4]\].

Currently, two new monovalent OPVs \[[@B5]\] and the change of the schedule from OPV to the exclusive use of inactivated polio vaccine (IPV) \[[@B6]\] represent options to interrupt PV transmission. However, it has been observed that reduction of exposure to a live attenuated virus such as that contained in OPV will inevitably lead to a decrease in herd immunity to a live microorganism and to natural boosters \[[@B7]\]. Such considerations, along with recent PV infection outbreaks, further complicate the issue of polio eradication \[[@B8]\].

In this scenario, new vaccine formulations and renewed research efforts might help to specifically fight PV infection. Recently, we analyzed the peptide overlap between PV1, strain Mahoney, and the human proteome and described a high extent of peptide sharing involving human proteins linked to fundamental cellular functions \[[@B9]\]. These data appeared to be of interest also because PV has been studied mainly at the nucleotide level \[[@B10]\], and, in general, there is a lack of knowledge of the interaction(s) between PV and the human host at the peptide/protein level. Actually, phenetic analyses of PV might help define peptide-based therapeutic approaches against PV infection, given that, for example,one single amino acid (aa) change, that is, His to Tyr at aa position 142 of virion protein 2 (VP2) or Val to Ile at aa position 160 of virion protein 1 (VP1), on the capsid surface of PV1 Sabin allows the establishment of persistent infections in HEp-2c cell cultures \[[@B11]\];replacement of the Ala residue with Asp at aa position 3 is linked to 50% loss of virion protein 4 (VP4) precursor myristoylation and severe reduction in specific infectivity \[[@B12]\];the 25th aa, Ile, of PV 2C protein interacts with human reticulon 3, a protein involved in viral replication and/or pathogenesis \[[@B13]\].

Moreover, since the 1980s we have known that small aa groupings can play a critical role in neutralizing PV. For example, the discontinuous E^4^T^7^T/S^8^R^9^ tetrapeptide, which is present in PV VP1, is crucial for neutralizing PV3 by anti-PV3 25-1-14 monoclonal antibody (mAb) \[[@B14]\]. Additional examples of short immune determinants in the immune response against PV are the following ones:A linear heptapeptide (DNNQTSP) is an Ab-binding site mapped to aa residues 164--170 of VP2 \[[@B15]\].Short synthetic peptides (e.g., DNTVRET, RSRSES, RSRSESSIESF, and STTNKDK) from PV VP1 prime the immune system of rabbits for a long-lasting, virus-neutralizing IgG Ab response following a single inoculation of intact virus \[[@B16]\].The Immune Epitope Database (IEDB; <http://www.immuneepitope.org>) \[[@B17]\] includes the continuous linear pentapeptide STTNK (IEDB ID: 61944) \[[@B18], [@B19]\] and the discontinuous pentapeptide T^141^E^143^S^312^E^315^P^417^ (IEDB ID: 91064) \[[@B20]\] as PV-derived epitopes.

Following the mathematical quantification of pentapeptide sharing between PV1 and human proteins, we reported that 2,040 out of the 2,204 pentamers composing the PV1 proteome are shared with the human proteome for a total of 18,223 matches, including multiple occurrences \[[@B9]\]. In general, a vast peptide sharing with human proteins is a characteristic of viral proteomes \[[@B21]\]. This peptide commonality suggests the existence of common evolutionary links between entities widely different as viruses and*Homo sapiens* and, in addition, indicates that potential cross-reactivity may affect antivirus vaccine formulations \[[@B22]\] and serological analyses \[[@B23]\]. Hence, it is reasonable to postulate that vaccines based on peptides unique to a virus and absent in the host proteome would guarantee high specificity and, at the same time, eliminate potential cross-reactivity.

Pursuing the objectives of overcoming the difficulties posed by the PV tendency to mutate and eliminating the viral reactivation-related VAPP in order to contribute to the global eradication of poliomyelitis, here we examine PV1 Mahoney polyprotein primary sequence and describe a set of pentapeptides uniquely owned by PV1, endowed with immunologic potential, and conserved among 43 PV strains. We propose that this set of pentapeptides might be used in preclinical and*in vivo* protocols with the ultimate aim of formulating effective, safe, and universal anti-PV vaccines.

2. Methods {#sec2}
==========

The primary aa sequence of human PV1 polyproteins, strain Mahoney (NCBI taxonomic identifier: 12081; Swiss-Prot/UniProtKB entry: P03300), consisting of 11 viral proteins, 2,209 aa long \[[@B24]\] (further details at <http://www.uniprot.org/uniprot/P03300>), was analyzed for aa sequence similarity to the human proteome at the pentapeptide level. In brief, the viral polyprotein was dissected into 5-mers sequentially overlapped by four residues: MGAQV, GAQVS, AQVSS, QVSSQ, VSSQK, and so forth; then, each viral pentapeptide was used as a probe to scan the human proteome for instances of the same pentapeptide, as already described \[[@B9]\]. The similarity analysis used the Protein Information Resource (PIR) peptide match program (<http://pir.georgetown.edu/>) \[[@B25]\].

PV-derived epitopes were retrieved from the Immune Epitope Database (IEDB; <http://www.immuneepitope.org>) \[[@B17]\]. Only PV epitopes that had been experimentally validated in the human host were considered in this study.

Consensus peptide sequences were defined by ClustalW multialignment analysis (<http://www.uniprot.org/program/?query=clustalw&sort=score>) \[[@B26]\] of sequences from 43 PV strains retrieved from UniProt database (<http://www.uniprot.org/>) on the basis of the following characteristics: (1) described in scientific literature; (2) corresponding to the entire PV polyprotein; (3) derived from PV1 and PV3; (4) derived from PV variants isolated from VAPP or acute flaccid paralysis (AFP) patients or from immunocompromised patients with residual paralysis. Description and references of the 43 PV sequences used for multialignment analysis are reported in detail at <http://www.uniprot.org/>; the relative Swiss-Prot/UniProtKB entries are P03300, P03301, P03302, P06209, Q9Q281, Q9Q280, Q71AZ9, Q5TLH5, D1YSI9, D1YSJ1, D1YSJ2, D1YSJ3, D1YSJ4, D1YSJ5, D1YSJ6, D1YSJ7, D1YSJ9, D1YSK1, D1YSK2, D1YSK3, D1YSK4, D1YSK5, D1YSK6, D1YSK7, D1YSK8, D1YSK9, D1YSL0, D1YSL1, D1YSL2, D1YSL3, D1YSL4, D1YSL5, D2X673, D8L541, B4YUL3, B4YUL4, Q84792, C5HJY2, C5HJY3, D1GE40, D2E679, D1GE41, and D2XUS9.

3. Results and Discussion {#sec3}
=========================

3.1. Identification of Pentapeptides Unique to PV Type 1, Strain Mahoney {#sec3.1}
------------------------------------------------------------------------

Using the procedure described under [Section 2](#sec2){ref-type="sec"}, we searched the human PV1, strain Mahoney, primary sequence for pentapeptides not shared with human proteins. We used pentapeptides as probes since a pentapeptide is a minimal functional unit in immunology \[[@B27]\], thus representing an appropriate length unit in measuring the qualitative/quantitative parameters of immunological phenomena \[[@B28]\].

[Table 1](#tab1){ref-type="table"} reports the pentapeptide platform that characterizes PV1 Mahoney polyprotein when compared to the*Homo sapiens* proteome. We find that 164 pentapeptides are unique to the viral polyprotein and absent in human proteins. In a few instances, viral 5-mers consecutively overlap ([Table 1](#tab1){ref-type="table"}, pentapeptides in bold), thus forming 6-, 7-, and 8-mer stretches (e.g., PV~163--169~QNMYYHY, PV~446--453~NYYTHWAG, PV~783--789~AYSHFYD, PV~1496--1498~KGWIVNI, PV~1594--1600~GIHDNVA, PV~1699--1706~RTLMYNFP, and PV~1750--1756~EIQWMRP).

3.2. Analysis of the Immunologic Potential of Peptides Unique to PV {#sec3.2}
-------------------------------------------------------------------

Next, the pentapeptides described in [Table 1](#tab1){ref-type="table"} were analyzed for their immunologic potential as follows. PV-derived epitopes were retrieved from IEDB, and the epitopes that had been experimentally validated in the human host were analyzed for the presence of pentapeptides unique to PV1 (see [Table 1](#tab1){ref-type="table"}).

As reported in [Table 2](#tab2){ref-type="table"}, the search through IEDB produced a final list of 78 viral epitopes derived from PV1 Mahoney, PV3 Sabin, and PV3 (P3/LEON/37 and P3/LEON 12A (1)B). Epitopes derived from PV2 strains were not considered since only data from immunoassays in mice, rats, and/or rabbits were available in IEDB for PV2 strains at the time of this study. Following sequence analysis, it was found that 20 of the 78 epitopes (i.e., IEDB IDs: 31814, 48785, 58511, 59797, 71769, 79272, 79480, 99910, 100138, 100244, 100349, 100382, 100536, 100576, 100631, 100667, 100672, 146181, 146248, and 146390; see IEDB IDs in bold in [Table 2](#tab2){ref-type="table"}) have a total of 12 viral pentapeptides that are absent in the human proteome (pentapeptides in capital letters in [Table 2](#tab2){ref-type="table"}). That is, a first conclusion from [Table 2](#tab2){ref-type="table"} is that 12 out of the 164 pentapeptides unique to PV1, strain Mahoney, are part of 20 PV epitopic sequences endowed with an immunologic potential in the human host.

Moreover, it can be seen that the 12 unique PV1 pentapeptides are not distributed at random among the PV-derived epitopes. For example, three unique pentapeptides (KWDDY, WDDYT, and YTWQT) overlap each other in the epitope IEDB ID 48785, sequence ppgapvpeKWDDYTWQTssnp (with unique overlapping pentapeptides in capital); the heptapeptide AYSHFYD, formed by three overlapping unique pentapeptides shifted by one residue, characterizes four PV-derived epitopes (IEDB IDs: 59797, 99910, 100244, and 100672); the hexapeptide SMMATG formed by two overlapped 5-mers is present in three epitopes (IEDB IDs: 146181, 146248, and 146390).

Theoretically, vaccines based on such PV epitopic peptides (i.e., KWDDYTWQT, AYSHFYD, and SMMATG) might evoke highly specific anti-PV immune responses exempt of possible collateral cross-reactions in the human host.

3.3. Identification of Consensus Pentapeptides Unique to PVs and Endowed with Immunologic Potential {#sec3.3}
---------------------------------------------------------------------------------------------------

We reasoned that using epitopic peptides unique to the virus and conserved among PV strains might help develop a global anti-PV peptide-based vaccination protocol. Such an approach would be of special importance in providing an effective and wide coverage to the human population worldwide, thus allowing reaching the goal of PV eradication \[[@B29], [@B30]\]. To this aim, we searched for unique conserved sequences by analysing a set of 43 PV polyproteins selected as described under [Section 2](#sec2){ref-type="sec"} and comprehending also PV variants isolated from faeces of VAPP or AFP or from immunocompromised patient(s) with residual paralysis. The 43 PV polyprotein sequences were aligned using multialignment ClustalW program \[[@B26]\] and the peptide sequences present in PV-derived epitopes (see [Table 2](#tab2){ref-type="table"}) and absent in the human proteome were localized.

[Table 3](#tab3){ref-type="table"} shows that seven potentially immunogenic peptides (in the order PV~465--469~MMATG, PV~708--712~RFDME, PV~752--756~DYTWQT, PV~763--767~FYTYG, PV~783--789~AYSHFYD, PV~835--839~KIRVY, and PV~847--851~VWCPR), derived from epitopes corresponding to (or formed of) pentapeptides unique to PV1 (see Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}), have 100% conservation among the 43 PV strains/variants under analysis. The seven potentially immunogenic unique peptide sequences had the same level of conservativeness in PV2 derived strains (data not shown).

4. Conclusion {#sec4}
=============

Anti-PV immunization has been one of the major public health measures of the last century. International campaigns to eliminate polio reduced the incidence of this disease in the world. However, problematic issues remain, such as the tendency of the PV genome to mutate, the potential risk to develop postvaccine paralytic poliomyelitis, and the difficulty to completely eradicate PV infection in the world. In fact, according to the World Health Organization, in 2012, still three countries in the world remain polio-endemic: Nigeria, Pakistan, and Afghanistan \[[@B31]\].

The present data propose the concept of sequence uniqueness as a tool to define specific immunotherapies exempt of collateral effects \[[@B22]\] and describe a methodology to identify PV peptides that have zero percent identity to human proteins, are endowed with an immunologic potential, and are highly conserved among PV strains (e.g., PV~465--469~MMATG, PV~708--712~RFDME, PV~752--756~DYTWQT, PV~763--767~FYTYG, PV~783--789~AYSHFYD, PV~835--839~KIRVY, and PV~847--851~VWCPR; see [Table 3](#tab3){ref-type="table"}). Importantly, polio peptide sequences alternate through the human proteome with a frequency versus rarity pattern that characterizes other pathogens too \[[@B32]--[@B35]\].

Theoretically, such viral consensus epitopic peptides appear to be ideal tools to generate anti-PV immune responses promising of high specificity, thus avoiding serological cross-reactivity between human polyomaviruses \[[@B23]\], as well as possible cross-reactions with the human host \[[@B22]\]. As an example, a construct composed of the coding frames corresponding to the immunogenic consensus sequences described above ([Table 2](#tab2){ref-type="table"}) might determine a specific anti-PV immune response and, at the same time, by being based on peptides, might eliminate the issues inherent to the tendency of the PV genome to mutate (i.e., VAPP). Such viral peptide sequences might also be used in passive anti-PV immunotherapies, that is, to produce specific antibodies capable of reacting with intact viral protein antigens.

Actually, the present report is intended to represent a first approach to preclinical and animal studies. As a matter of fact, the solidity of a large body of theoretical and*in silico* data is the mandatory basis to design*in vivo* experimentation and validation protocols especially when considering that (i) although monkeys can be experimentally infected, humans are the only known natural hosts of poliovirus; (ii) small animal models for testing polio pathogenesis mainly relate to transgenic mice to express a human receptor to poliovirus \[[@B36]\]; and, moreover, (iii) current laws on*in vivo* experimentation are increasingly restrictive.
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###### 

Pentapeptides unique to PV type 1, strain Mahoney, and absent in the human proteome.

  Pos^a^   Sequence^b,c^   Pos^a^   Sequence^b,c^   Pos^a^   Sequence^b,c^   Pos^a^   Sequence^b,c^   Pos^a^   Sequence^b,c^   Pos^a^   Sequence^b,c^
  -------- --------------- -------- --------------- -------- --------------- -------- --------------- -------- --------------- -------- ---------------
  11       GAHEN           393      MIPLN           746      PAKWD           969      YYPAR           1399     CHQPA           1750     **EIQWM**
  29       TINYY           403      KNTMD           748      KWDDY           974      YQSHI           1403     ANFKR           1751     **IQWMR**
  72       NIEAC           404      NTMDM           749      WDDYT           996      CHHGV           1413     CGKAI           1752     **QWMRP**
  73       IEACG           408      MYRVQ           752      YTWQT           1014     FADIR           1418     QLMDK           1762     YPIIN
  104      YGRWP           414      NDNPH           763      FYTYG           1021     YAYEE           1437     IVNER           1810     YVGNK
  106      RWPEY           436      LSHTM           783      **AYSHF**       1084     ITRNY           1458     PIQYK           1840     TEQMC
  107      WPEYL           446      **NYYTH**       784      **YSHFY**       1105     VSPWQ           1475     ECIND           1849     MYGTD
  130      CRFYT           447      **YYTHW**       785      **SHFYD**       1136     TEACN           1489     VRNYC           1933     VAMRM
  145      RGWWW           448      **YTHWA**       835      KIRVY           1139     CNAAK           1490     RNYCE           1935     MRMAF
  146      GWWWK           449      **THWAG**       841      KPKHI           1188     STIHQ           1496     **KGWIV**       1946     FHKNP
  148      WWKLP           464      SMMAT           847      VWCPR           1190     IHQSC           1497     **GWIVN**       1947     HKNPG
  149      WKLPD           465      MMATG           857      AYYGP           1204     FNNVR           1498     **WIVNI**       1966     WSKIP
  163      **QNMYY**       494      HVIWD           863      VDYKD           1205     NNVRW           1513     NRAMT           1979     AFDYT
  164      **NMYYH**       495      VIWDI           880      TYGFG           1209     WLSIQ           1532     VYVMY           1983     TGYDA
  165      **MYYHY**       497      WDIGL           881      YGFGH           1231     LEHTI           1534     VMYKL           1993     WFEAL
  179      VQCNA           507      MVVPW           883      FGHQN           1291     FDGYK           1536     YKLFA           2028     YCVKG
  199      MCLAG           510      PWISN           884      GHQNK           1311     GADMK           1588     GEFTM           2070     KMIAY
  242      RFCPV           518      RQTTN           894      GYKIC           1314     MKLFC           1592     MLGIH           2073     AYGDD
  244      CPVDY           534      FYQTR           895      YKICN           1326     FIPPM           1594     **GIHDN**       2115     TWENV
  271      TNNCA           556      SACND           897      ICNYH           1340     FTSNY           1595     **IHDNV**       2131     KYPFL
  292      KHNNW           557      ACNDF           912      VSTMW           1341     TSNYV           1596     **HDNVA**       2148     SIRWT
  293      HNNWG           558      CNDFS           914      TMWDR           1368     RFAFD           1660     TETND           2158     TQDHV
  295      NWGIA           568      DTTHI           934      ARCNC           1369     FAFDM           1677     MFVPV           2168     LAWHN
  323      PMCC            569      TTHIG           942      VYYCE           1371     FDMDI           1699     **RTLMY**       2201     LYRRW
  324      PMCCE           588      MIDNT           948      RRKYY           1388     DMTMA           1700     **TLMYN**                 
  326      CCEFN           665      CVSII           959      PTFQY           1389     MTMAT           1701     **LMYNF**                 
  327      CEFNG           708      RFDME           961      FQYME           1394     EMCKN           1702     **MYNFP**                 
  391      DTMIP           735      QIMYV           962      QYMEA           1398     NCHQP           1742     SYFTQ                     

^a^aa position along the human PV type 1, strain Mahoney, primary sequence.

^b^aa sequences given in one-letter code.

^c^Consecutively overlapping pentapeptides forming 7- and 8-mer stretches unique to PV are given in bold.

###### 

Twelve pentapeptides unique to PV1, Mahoney strain, and absent in the human proteome are distributed among twenty PV-derived epitopes recognized by human sera and/or T cells.

  IEDB ID^a^   Epitope sequence^b,c^       PV antigen    PV strain                               Immune context
  ------------ --------------------------- ------------- --------------------------------------- ----------------
  30661        kevpaltavetgat              VP1           PV3 Sabin                               B
  **31814**    **klefftysRFDMEltfvvtan**   VP1           PV1 Mahoney                             T
  46859        paltavetgatnpl              VP1           PV1 Mahoney                             B-T
  **48785**    **ppgapvpeKWDDYTWQTssnp**   VP1           PV1 Mahoney                             T
  55952        rsrsessiesf                 VP1           PV1 Mahoney                             B
  **58511**    **siFYTYGtaparisvpyvgi**    VP1           PV1 Mahoney                             T
  **59797**    **snAYSHFYDgfskvplkdqs**    VP1           PV1 Mahoney                             T
  66978        tvdnsasttnkdklfavwk         Polyprotein   PV1 Mahoney                             T
  **71769**    **vvndhnptkvtsKIRVYlkp**    Polyprotein   PV1 Mahoney                             T
  79155        altlslpkqqdslpdtka          Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79160        atnplapsdtvqtrhvvq          Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79186        dneqpttraqklfam             Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79269        kevpaltavetgatnpla          Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  **79272**    **khvrVWCPRppravpyyg**      Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79318        nghalnqvyqimyippga          Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79350        qklfamwritykdtv             Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79354        qpttraqklfamwri             Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79433        traqklfamwrityk             Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79434        traqklfamwritykdtv          Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79435        trhvvqrrsrsestiesf          Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79436        tskvriymkpkhvrvw            Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79443        vaiievdneqpttraqkl          Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  79461        vrvvndhnptkvtskvri          Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  **79480**    **yippgaptpksWDDYTwq**      Polyprotein   PV3 (P3/LEON/37 and P3/LEON 12A (1)B)   T
  80446        argacvtimtvdnpa             VP1           PV1 Mahoney                             B
  81394        easgpthskeipalt             VP1           PV1 Mahoney                             B
  82831        gpthskeipaltave             VP1           PV1 Mahoney                             B
  83234        hskeipaltavetga             VP1           PV1 Mahoney                             B
  88446        sdtvqtrhvvqhrsr             VP1           PV1 Mahoney                             B
  88495        sessiesffargacv             VP1           PV1 Mahoney                             B
  99863        aaparisvpyvgla              Polyprotein   PV3 Sabin                               B
  99886        ahskevpaltavet              Polyprotein   PV3 Sabin                               B
  99901        arisvpyvglanay              Polyprotein   PV3 Sabin                               B
  **99910**    **AYSHFYDgfakvpl**          Polyprotein   PV3 Sabin                               B
  99933        dfgvlavrvvndhn              Polyprotein   PV3 Sabin                               B
  99963        dtvqlrrkleffty              Polyprotein   PV3 Sabin                               B
  100029       famwritykdtvql              Polyprotein   PV3 Sabin                               B
  100101       hfydgfakvplktd              Polyprotein   PV3 Sabin                               B
  100117       hnptkvtskvriym              Polyprotein   PV3 Sabin                               B
  **100138**   **iFYTYGaaparisv**          Polyprotein   PV3 Sabin                               B
  **100244**   **lanAYSHFYDgfak**          Polyprotein   PV3 Sabin                               B
  **100349**   **npsiFYTYGaapar**          Polyprotein   PV3 Sabin                               B
  **100382**   **pkhvrVWCPRppra**          Polyprotein   PV3 Sabin                               B
  100391       psdtvqtrhvvqrr              Polyprotein   PV3 Sabin                               B
  100425       qklfamwritykdt              Polyprotein   PV3 Sabin                               B
  100430       qlrrklefftysrf              Polyprotein   PV3 Sabin                               B
  100439       qpttraqklfamwr              Polyprotein   PV3 Sabin                               B
  100482       rppravpyygpgvd              Polyprotein   PV3 Sabin                               B
  100492       samtvddfgvlavr              Polyprotein   PV3 Sabin                               B
  100504       sevaqgaltlslpk              Polyprotein   PV3 Sabin                               B
  **100536**   **svpyvglanAYSHF**          Polyprotein   PV3 Sabin                               B
  100559       tkvtskvriymkpk              Polyprotein   PV3 Sabin                               B
  100573       traqklfamwrity              Polyprotein   PV3 Sabin                               B
  100575       tskvriymkpkhvr              Polyprotein   PV3 Sabin                               B
  **100576**   **tssnpsiFYTYGaa**          Polyprotein   PV3 Sabin                               B
  100580       tvddfgvlavrvvn              Polyprotein   PV3 Sabin                               B
  100583       tvqtrhvvqrrsrs              Polyprotein   PV3 Sabin                               B
  100585       twqtssnpsifyty              Polyprotein   PV3 Sabin                               B
  100586       tygaaparisvpyv              Polyprotein   PV3 Sabin                               B
  100587       tykdtvqlrrklef              Polyprotein   PV3 Sabin                               B
  100613       vlavrvvndhnptk              Polyprotein   PV3 Sabin                               B
  100619       vndhnptkvtskvr              Polyprotein   PV3 Sabin                               B
  100628       vriymkpkhvrvwc              Polyprotein   PV3 Sabin                               B
  100630       vrvvndhnptkvts              Polyprotein   PV3 Sabin                               B
  **100631**   **vrVWCPRppravpy**          Polyprotein   PV3 Sabin                               B
  100638       wcprppravpyygp              Polyprotein   PV3 Sabin                               B
  100644       writykdtvqlrrk              Polyprotein   PV3 Sabin                               B
  **100667**   **ymkpkhvrVWCPRp**          Polyprotein   PV3 Sabin                               B
  **100672**   **yvglanAYSHFYDg**          Polyprotein   PV3 Sabin                               B
  146178       ayappgaqpptsrk              Polyprotein   PV3 Sabin                               B
  **146181**   **cgSMMATGkilvay**          Polyprotein   PV3 Sabin                               B
  **146248**   **flfcgSMMATGkil**          Polyprotein   PV3 Sabin                               B
  146311       hqgalgvfaipeyc              Polyprotein   PV3 Sabin                               B
  146333       ilvayappgaqppt              Polyprotein   PV3 Sabin                               B
  **146390**   **kftflfcgSMMATG**          Polyprotein   PV3 Sabin                               B
  146494       phqiinlrtnnsat              Polyprotein   PV3 Sabin                               B
  146496       ppgaqpptsrkeam              Polyprotein   PV3 Sabin                               B
  146516       ravpyygpgvdyrn              Polyprotein   PV3 Sabin                               B

^a^PV-derived epitopes are listed according to increasing IEDB ID number. Further details and reference(s) on each IEDB ID are reported at <http://www.immuneepitope.org> \[[@B17]\].

^b^Only PV-derived epitopes that had been experimentally validated in the human host are reported.

^c^The twenty PV-derived epitopes (and related IDs) containing PV-pentapeptide(s) absent in the human proteome are in bold, with the pentapeptide(s) absent in the human proteome given in capital.

###### 

Conservativeness of epitopic PV peptide regions among 43 PV strains and variants.

  --------------------------------------------------------------------------------------------------------------------------------------------
  PV strain                 UniProt/Swiss-Prot entry   aa Pos 464   aa Pos 708   aa Pos 748   aa Pos 763   aa Pos\   aa Pos 835   aa Pos 847
                                                                                                           783                    
  ------------------------- -------------------------- ------------ ------------ ------------ ------------ --------- ------------ ------------
  PV1 Mahoney               P03300                     FMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1 Sabin                 P03301                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV3 P3/Leon/37            P03302                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRiY        VWCPR

  PV3 23127                 P06209                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRvY        VWCPR

  PV1 isolated              Q9Q281                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KvRVY        VWCPR

  PV1 isolated              Q9Q280                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1 isolated              Q71AZ9                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1 isolated              Q5TLH5                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-HAI01008C2            D1YSI9                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-HAI01009              D1YSJ1                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-HAI01008              D1YSJ2                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-HAI01002              D1YSJ3                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-HAI01001              D1YSJ4                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR01012              D1YSJ5                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR01002C             D1YSJ6                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR01002              D1YSJ7                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR01001C1            D1YSJ9                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00042C2            D1YSK1                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00042C1            D1YSK2                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00042              D1YSK3                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00041C3            D1YSK4                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00041C2            D1YSK5                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00044              D1YSK6                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00028C             D1YSK7                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00028              D1YSK8                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00023C             D1YSK9                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00025              D1YSL0                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOOR24                D1YSL1                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00015              D1YSL2                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-DOR00016              D1YSL3                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-HAI01013all           D1YSL4                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-HAI01015              D1YSL5                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV1-S302                  D2X673                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  CHN8184/GZ/CHN/2004       D8L541                     SMMATG       RFDME        KWDDYTWQT    FYTYG        AYSHFYD   KIRVY        VWCPR

  PV3 isolated              B4YUL3                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRVY        VWCPR

  PV3 isolated              B4YUL4                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRVY        VWCPR

  PV3 (vacc.StrainSabin3\   Q84792                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRiY        VWCPR
  (Leon 12a1b))                                                                                                                   

  PV3-33239                 C5HJY2                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRiY        VWCPR

  PV3-31974                 C5HJY3                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRiY        VWCPR

  PV3-FIN84-60212           D1GE40                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRiY        VWCPR

  PV3-SWI10947              D2E679                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRiY        VWCPR

  PV3-FIN84-2493            D1GE41                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRiY        VWCPR

  PV3-P3/Jinan/1/09         D2XUS9                     SMMATG       RFDME        sWDDYTWQT    FYTYG        AYSHFYD   KvRiY        VWCPR
  --------------------------------------------------------------------------------------------------------------------------------------------

The 43 PV sequences were aligned using ClustalW multialignment program (<http://www.uniprot.org/align/>) \[[@B26]\]. The analyzed PV sequences and related references are described at <http://www.uniprot.org/> and reported by Swiss-Prot/UniProtKB accession number. Peptide sequences present in PV-derived epitopes (see [Table 2](#tab2){ref-type="table"}) and absent in the human proteome were localized along the 43 aligned PV sequences and analyzed for conservativeness. Peptide sequences are indicated by their position along the PV polyprotein. Mutated aa residues are in lower case.

[^1]: Academic Editor: Yoshihiko Hoshino
